AKEBIA THERAPEUTICS, INC. AKBA Cash Flow

Akebia therapeutics, inc. (AKBA)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14
Operating activities:
Net loss
-60,747	-94,483	-54,585	-58,170	-72,421	-60,054	-26,047	-34,069	-23,418	15,523	-23,134	-21,517	-44,543	-37,862	-36,308	-35,779	-25,798	-19,857	-19,475	-10,689	-10,695	-10,370	-9,349	-7,618	-9,697
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
525	586	633	587	439	261	225	214	199	197	167	118	135	124	94	46	32	11	35	31	19	16	13	12	8
Amortization of intangibles
9,100	9,100	9,101	9,100	9,100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of premium/discount on investments
-	24	110	208	477	534	385	253	60	-67	-154	-198	-191	-95	-112	-143	-144	-140	-147	-136	-135	-	-	-	-
Non-cash interest expense
437	278	169	170	169	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash operating lease expense
-647	-556	-576	-483	-614	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fair value write-up of inventory sold
11,180	18,840	18,017	19,001	14,586	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Write-down of inventory
100	1,144	2,945	1,323	1,700	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation
4,916	4,934	2,613	2,284	2,094	12,062	2,253	2,493	2,232	2,193	2,152	2,506	2,016	-	-	-	-	1,328	1,163	1,095	1,128	885	1,236	1,444	2,445
Deferred income taxes
-	-1,752	-1,277	-845	-2,757	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of derivative liability
90	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fair value of warrants issued for license
-	-	-	-	-	-	-	-	-	0	0	0	3,413	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Accounts receivable
66,008	9,210	766	-19,547	31,769	144	556	-35,720	1,636	33,935	281	0	-33,823	-	-	-	-	-	-	-	-	-	-57	-5	-16
Inventory
8,163	577	11,377	1,124	16,064	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other current assets
1,898	-1,126	-20,752	12,654	-1,317	631	1,532	-2,682	1,496	2,396	-7,222	7,926	1,093	-1,691	-48	1,369	-58	1,225	-834	-191	801	-2	-262	230	720
Other long-term assets
-46	-1,772	226	-2,652	-719	-	-	-	-	987	-75	78	1	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable
20,470	-25,066	46,066	1,118	-20,746	8,031	7,889	-13,085	10,882	-1,707	-1,507	-4,871	13,044	-6,470	3,366	2,728	102	-3,021	2,861	-1,917	2,308	-	-	-	-
Accrued expense
-4,209	1,825	-1,050	-10,626	-17,500	13,364	13,571	26,148	2,399	30,808	-7,287	-5,545	3,998	12,686	1,655	4,905	1,457	622	5,402	-967	-411	-	-	-	-
Operating lease liabilities
445	954	505	523	549	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
4,735	-3,079	-19,845	-10,597	-6,218	-38,834	-7,980	-10,730	-9,391	-26,108	-32,145	61,454	-20,866	157,289	0	0	40,000	-	-	-	-	-	-	-	-
Deferred rent
-	-	-	-	-	549	-45	-45	-41	-33	-33	25	355	218	856	1,149	188	-	-	-	-	-	-	-	-
Net cash used in operating activities
-89,589	-92,135	10,989	-38,366	-137,929	-73,699	-12,461	8,996	-20,330	-16,378	-54,617	24,364	-9,528	95,670	-28,243	-26,955	17,434	-22,912	-9,031	-12,117	-8,347	-9,203	-5,603	-6,669	-6,008
Investing activities:
Accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,080	-307	1,910
Other liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-30	-	-1	0	30
Purchase of equipment
-	220	2,529	1,978	1,928	830	307	173	296	450	597	148	427	48	1,256	1,249	109	72	115	27	200	21	37	29	142
Proceeds from the maturities of available for sale securities
245	22,500	26,919	25,000	78,691	63,178	57,288	66,473	56,330	52,130	43,750	29,628	24,490	37,225	60,277	49,560	15,314	14,354	14,757	25,205	9,585	5,595	245	1,245	5,500
Proceeds from sales of available for sale securities
-	0	0	31,011	33,710	0	5,002	2,999	4,999	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of available for sale securities
-	-	-	-	-	51,778	50,972	72,867	48,599	64,988	88,112	61,170	116,366	14,871	13,454	18,524	100,160	12,644	29,097	29,454	5,980	-	-	-	-
Net cash provided by investing activities
245	22,280	24,390	54,033	110,473	16,717	11,011	-3,568	12,434	-8,308	-44,959	-31,690	-92,303	22,306	45,567	29,787	-84,955	1,638	-14,455	-4,276	3,405	-7,637	-39,998	-23,075	5,358
Proceeds from the issuance of redeemable convertible preferred stock, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	105,754
Proceeds from the issuance of common stock, net of issuance costs
56,485	-	-	-	-	-1	38	-96	95,511	5,039	62,629	45,357	1,555	3,531	2,336	-297	61,166	-	-	-	-	-	-	-	-
Proceeds from the sale of stock under employee stock purchase plan
451	0	195	0	188	0	265	-1	218	1	227	0	125	-	-	-	-	111	0	59	50	-	-	-	-
Proceeds from the exercise of stock options
412	0	0	195	365	92	58	314	183	204	930	110	68	-1	5	101	19	-	-	-	-	-	-	-	-
Payments on debt
-	0	0	0	15,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments on capital lease obligations
-	-	-	-	-	6	7	5	1	1	1	1	2	1	13	3	3	2	2	2	1	-	-	-	-
Net cash provided by financing activities
57,348	94,418	195	8,804	-14,447	85	354	212	95,911	5,243	63,785	45,466	1,746	3,529	2,329	-94	61,182	4,340	13,950	64,754	49	-48	-125	-1,181	105,754
Increase in cash, cash equivalents, and restricted cash
-31,996	24,563	35,574	24,471	-41,903	-56,897	-1,096	5,640	88,015	-19,443	-35,791	38,140	-100,085	121,505	19,653	2,738	-6,339	-16,934	-9,536	48,361	-4,893	-16,888	-45,726	-30,925	105,104
Non-cash financing activities
Unpaid offering costs
90	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unpaid initial public offering issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14,879	-1,048	1,169
Unpaid follow-on offering costs
-	-	-	-	-	-	-	-	95	-	-	127	10	-53	-66	111	20	-	-	-	55	-	-	-	-
Assets acquired under capital lease
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	12	-	0	0	12